Rare FNIP1 Variants Track Better Metabolism
A million-person genetics study links rare FNIP1 loss-of-function variants to favourable metabolic traits, but it does not show that blocking the gene is a safe or effective treatment.
The 60-second version
Ultra-rare FNIP1 loss-of-function variants tracked with favourable metabolic traits in a million-person genetics study.
Key points
- The variants occurred in roughly one of every 7,000 sequenced people and were associated with lower liver fat, glycaemia and atherogenic lipids.
- The composite cardiometabolic disease odds ratio was 0.39, but this was an association rather than a treatment effect.
- Human liver-cell experiments supported lipid-catabolism signalling, while Fnip1 inhibition alone did not protect diet-challenged mice.
- Safety is unresolved, and many authors have Regeneron employment, equity or related patent interests.
Verdict. A credible therapeutic hypothesis built on unusually large human genetics data, but not yet a drug, a clinical recommendation or proof of safe FNIP1 inhibition.
Bottom lineWhat the study found
Researchers analysed exome sequences from 1,032,116 people and found that ultra-rare protein-truncating variants in FNIP1 were associated with a favourable cluster of metabolic traits. The work identifies a plausible biological pathway, not a validated therapy.
Carriers had lower triglyceride-to-HDL cholesterol ratios, lower liver fat and glycated haemoglobin, and more favourable fat distribution. These are associations among people born with variants; they do not demonstrate that deliberately inhibiting FNIP1 later in life will reproduce the same balance of effects.
DesignThree evidence layers
| Human genetics | Exome association analysis across cohorts in America, Europe and Asia; 59 genes met the study-wide threshold. |
|---|---|
| Disease analysis | 227,636 cases and 265,114 controls for a composite of coronary disease, type 2 diabetes, metabolic liver disease and cirrhosis. |
| Human cells | Primary hepatocytes with FNIP1 siRNA knockdown; six biological replicates per group, independently repeated. |
| Animal mechanism | Male mice on a high-fat, high-fructose diet; approximately 11–12 animals per liver-editing group. |
| What was not done | No drug trial, no therapeutic FNIP1 inhibition in people and no clinical efficacy endpoint. |
The main phenotype was the triglyceride-to-HDL ratio, used here as an energy-state biomarker. A higher ratio was associated with multiple cardiometabolic traits in the study population, but it remains a biomarker rather than a treatment outcome.
EffectHow to read the 60 percent figure
Among heterozygous carriers, FNIP1 loss-of-function variants were associated with around 60% lower odds of the composite disease outcome: odds ratio 0.39, 95% confidence interval 0.22–0.69. The composite grouped several different diseases, and an odds ratio cannot be converted directly into an individual's absolute risk without baseline risk and follow-up context.
A protective genetic association can nominate a target; it cannot certify a drug.
MechanismCells and mice support a pathway
Reducing FNIP1 messenger RNA by more than 90% in primary human hepatocytes increased expression of lysosomal and lipid-catabolism genes. In mice, however, liver inhibition of Fnip1 alone did not protect against weight gain. Benefit appeared after combined Fnip1 and Fnip2 inhibition or after inhibiting their interactor Flcn.
The combined interventions reduced fat gain, liver triglycerides and insulin measures in groups of roughly 11–12 mice. These experiments strengthen biological plausibility while also exposing a species difference or functional redundancy that future work must resolve.
LimitsSafety and conflicts matter
- Complete biallelic FNIP1 loss is linked to a rare recessive immunodeficiency syndrome; partial, tissue-specific and systemic inhibition may have different risks.
- The authors note other mouse evidence of liver injury and carcinogenesis after liver-cell Flcn knockout, despite favourable liver measures in the current models.
- The disease estimate used a composite outcome and observational clinical records, not prospectively adjudicated treatment endpoints.
- The animal experiments described here used male mice, limiting conclusions about sex-dependent effects.
- Long-term human efficacy and safety have not been tested.
Practical meaningWhat to do now
Do not use this study to change medication, seek consumer FNIP1 testing or infer that a protective variant cancels ordinary metabolic risks. The useful next signals are independent cohort replication, tissue-specific toxicology and controlled human trials that measure both clinical outcomes and adverse effects.